Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but Alexion (NASDAQ: ALXN )
is following a somewhat different path. While I do not mean to give
short shrift to this company's pipeline development efforts, the fact is
that Alexion has been more interested in maximizing the value of its
blockbuster orphan drug Soliris than relying on new development
projects. That strategy has served the company well so far, and while
there may some reasons to question whether health care systems will
continue to support such generous reimbursement for orphan drugs,
Soliris could yet offer significant growth potential.
Read more here:
Can Alexion Pharmaceuticals Continue to Deliver?
No comments:
Post a Comment